Fingerprint
Dive into the research topics where Brendan Curti is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response
Curti, B. (PI) & Redmond, W. (CoPI)
08/2/21 → 07/31/27
Project: Research
-
Augmenting OX40 Immunotherapy in Men with Advanced Prostate Cancer
Curti, B. (PI)
01/1/10 → …
Project: Research
-
Ipilimumab plus a galectin-3 inhibitor for metastatic melanoma
Curti, B. (PI) & Redmond, W. (CoPI)
07/6/15 → 06/30/16
Project: Research
-
Clinical and Immunological Effects of SBRT and IL-2 in Metastatic Melanoma
Crittenden, M. (PI) & Curti, B. (CoPI)
04/1/13 → 03/31/16
Project: Research
-
-
Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non–Small Cell Lung Cancer
Sako, C., Kurland, B. F., Schmidt, T. G., He, J., De Groot, M., Patel, A. A., Owen, D. H., Amini, A., Curti, B. D., Kelly, R. J., Page, R. D., Swalduz, A., Beregi, J. P., Chrusciel, J., Sanchez, S., Weiss, J., Liu, A., Gevaert, O., Hart, A. & Simon, G. R. & 3 others, , Jan 28 2026, In: JAMA Network Open. 9, 1, e2555759.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Checkpoint Immunotherapy for Melanoma - Offering Hope for Cure.
Curti, B. D., Jan 2 2025, In: New England Journal of Medicine. 392, 1, p. 81-82 2 p.Research output: Contribution to journal › Editorial
6 Scopus citations -
Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial
Park, J. C., Curti, B., Butler, M., Wehrenberg-Klee, E., Elassal, J., Tighe, R., Battula, S., Iodice, G., Kaufman, H. L. & Kirkwood, J. M., Dec 2025, In: Nature Communications. 16, 1, 8567.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study
Medina, T., Chesney, J. A., Kluger, H. M., Hamid, O., Whitman, E. D., Cusnir, M., Thomas, S. S., Wermke, M., Domingo-Musibay, E., Phan, G. Q., Kirkwood, J. M., Larkin, J., Weber, J., Graf Finckenstein, F., Chou, J., Gastman, B., Wu, X., Fiaz, R., Sarnaik, A. A. & for the C-144-01 Investigators, T.C.-1.-0. I. & 26 others, , Nov 20 2025, In: Journal of Clinical Oncology. 43, 33, p. 3565-3572 8 p.Research output: Contribution to journal › Article › peer-review
33 Scopus citations -
ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC): updated safety and efficacy from the phase 1 TRAVERSE multicenter study
Srour, S., Curti, B. & comments, S. F. L. O. A. I., Nov 1 2024Research output: Other contribution